Senores Pharma acquires Zoraya, receives EIR from FDA

7 Nov 2025 · 16:06 ISTafter close1 source ↓written by the desknot a recommendation

in Zoraya Pharmaceuticals: 51% stake

Senores Pharmaceuticals announced the acquisition of a 51% stake in Zoraya Pharmaceuticals, enhancing its US operations. Additionally, its subsidiary, Havix Group, received an Establishment Inspection Report (EIR) from the USFDA after resolving three minor observations from a July 2025 inspection. These developments strengthen Senores' regulatory position in the US market.

Not investment advice. For informational purposes only.

OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 7 Nov 2025, 16:06 IST.

Sourcesnews.google.com

Senores Pharma acquires Zoraya, receives EIR from FDA

Related